On August 13, Cansino Biotech Co., Ltd. (hereinafter referred to as "Cansino") was listed on the Science and Technology Innovation Board and became the first "A+H" vaccine stock to be listed on the Science and Technology Innovation Board. On the opening day, Cansino shares rose 124% to 470 yuan/share (RMB, the same below). As of the close, Cansino closed at 393.11 yuan/share, an increase of 87.45%.
Under the aura of "new crown vaccine first stock" and "Hong Kong stock vaccine leader", the market has high expectations for CanSino. The issue price of Cansino is 209.71 yuan/share, which is the second highest issue price in the history of China’s A-shares, second only to Beijing Stone Century Technology Co., Ltd., which was listed on the Science and Technology Innovation Board, at 271.12 yuan/share.
It is understood that Cansino is currently developing 16 vaccines under development for 13 disease fields and has obtained 19 authorized invention patents. The research and development pipeline covers the prevention of meningitis, Ebola virus disease, DPT, tuberculosis, and recombinant new coronavirus Viral vaccines (adenovirus vectors), herpes zoster, and many other vaccine varieties with large clinical demand.
(Edited by Gao Zhimiao, Kang Yuzhan, Lu Jie)
Editor in charge: 【Luo Pan】